Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data

Stella G Muthuri*, Sudhir Venkatesan*, Puja R Myles, Jo Leonardi-Bee, Tarig S A Al Khuwaitir, Adbullah Al Mamun, Ashish P Anovadiya, Eduardo Azziz-Baumgartner, Clarisa Báez, Matteo Bassetti, Bojana Beovic, Barbara Bertisch, Isabelle Bonmarin, Robert Booy, Victor H Borja-Aburto, Heinz Burgmann, Bin Cao, Jordi Carratala, Justin T Denholm, Samuel R Dominguez, Pericles A D Duarte, Gal Dubnov-Raz, Marcela Echavarria, Sergio Fanella, Zhancheng Gao, Patrick Gérardin, Maddalena Giannella, Sophie Gubbels, Jethro Herberg, Anjarath L Higuera Iglesias, Peter H Hoger, Xiaoyun Hu, Quazi T Islam, Mirela F Jiménez, Amr Kandeel, Gerben Keijzers, Hossein Khalili, Marian Knight, Koichiro Kudo, Gabriela Kusznierz, Ilija Kuzman, Arthur M C Kwan, Idriss Lahlou Amine, Eduard Langenegger, Kamran B Lankarani, Yee-Sin Leo, Rita Linko, Pei Liu, Faris Madanat, Elga Mayo-Montero, Allison McGeer, Ziad Memish, Gokhan Metan, Auksė Mickiene, Dragan Mikić, Kristin G I Mohn, Ahmadreza Moradi, Pagbajabyn Nymadawa, Maria E Oliva, Mehpare Ozkan, Dhruv Parekh, Mical Paul, Fernando P Polack, Barbara A Rath, Alejandro H Rodríguez, Elena B Sarrouf, Anna C Seale, Bunyamin Sertogullarindan, Marilda M Siqueira, Joanna Skręt-Magierło, Frank Stephan, Ewa Talarek, Julian W Tang, Kelvin K W To, Antoni Torres, Selda H Törün, Dat Tran, Timothy M Uyeki, Annelies Van Zwol, Wendy Vaudry, Tjasa Vidmar, Renata T C Yokota, Paul Zarogoulidis, PRIDE Consortium Investigators†, Jonathan S Nguyen-Van-Tam

Summary

Background Neuraminidase inhibitors were widely used during the 2009–10 influenza A H1N1 pandemic, but evidence for their effectiveness in reducing mortality is uncertain. We did a meta-analysis of individual participant data to investigate the association between use of neuraminidase inhibitors and mortality in patients admitted to hospital with pandemic influenza A H1N1pdm09 virus infection.

Methods We assembled data for patients (all ages) admitted to hospital worldwide with laboratory confirmed or clinically diagnosed pandemic influenza A H1N1pdm09 virus infection. We identified potential data contributors from an earlier systematic review of reported studies addressing the same research question. In our systematic review, eligible studies were done between March 1, 2009 (Mexico), or April 1, 2009 (rest of the world), until the WHO declaration of the end of the pandemic (Aug 10, 2010); however, we continued to receive data up to March 14, 2011, from ongoing studies. We did a meta-analysis of individual participant data to assess the association between neuraminidase inhibitor treatment and mortality (primary outcome), adjusting for both treatment propensity and potential confounders, using generalised linear mixed modelling. We assessed the association with time to treatment using time-dependent Cox regression shared frailty modelling.

Findings We included data for 29 234 patients from 78 studies of patients admitted to hospital between Jan 2, 2009, and March 14, 2011. Compared with no treatment, neuraminidase inhibitor treatment (irrespective of timing) was associated with a reduction in mortality risk (adjusted odds ratio [OR] 0·81; 95% CI 0·70–0·93; p=0·0024). Compared with later treatment, early treatment (within 2 days of symptom onset) was associated with a reduction in mortality risk (adjusted OR 0·48; 95% CI 0·41–0·56; p<0·0001). Early treatment versus no treatment was also associated with a reduction in mortality (adjusted OR 0·50; 95% CI 0·37–0·67; p<0·0001). These associations with reduced mortality risk were less pronounced and not significant in children. There was an increase in the mortality hazard rate with each day's delay in initiation of treatment up to day 5 as compared with treatment initiated within 2 days of symptom onset (adjusted hazard ratio [HR 1·23] [95% CI 1·18–1·28]; p<0·0001 for the increasing HR with each day's delay).

Interpretation We advocate early instigation of neuraminidase inhibitor treatment in adults admitted to hospital with suspected or proven influenza infection.

Funding F Hoffmann-La Roche.

Introduction

The neuraminidase inhibitors, oral oseltamivir and inhaled zanamivir, were the predominant medical countermeasure available from emergence of the influenza A H1N1pdm09 virus in early 2009, until the first release of monovalent H1N1 vaccines in October, 2009. Prescribing data from seven countries (Australia, Canada, France, Germany, Japan, UK, USA) suggest at least 18·3 million individuals received oseltamivir between May 1, 2009, and Dec 31, 2009.[1] Country-specific policies for use of neuraminidase inhibitors during the 2009–10 pandemic varied from no use, to targeted use in at-risk patients (most countries), to treatment of all patients with clinical illness (UK). Most use of neuraminidase inhibitors worldwide was in the form of oseltamivir—eg, 97·5% of neuraminidase inhibitors used in the USA.[2]

Division of Epidemiology and Public Health, University of Nottingham, Nottingham, UK (S G Muthuri PhD, S Venkatesan MPH, P R Myles PHD, J Leonardi-Bee PhD, Prof J S Nguyen-Van-Tam DM); **Department of Medicine, King Saud Medical City, Riyadh, Saudi Arabia** (T S A Al Khuwaitir FRCP); **International Centre for Diarrhoeal Diseases, Research Bangladesh, Dhaka, Bangladesh** (A Al Mamun MPH); **Department of Pharmacology, Government Medical College Bhavnagar, Gujarat, India** (A P Anovadiya MD Pharm); **Sir Takhtsinhji General Hospital, Bhavnagar, Gujarat, India** (A P Anovadiya); **Centers for Disease Control and Prevention, Atlanta, GA, USA** (E Azziz-Baumgartner MD); **Ministerio de Salud de la Provincia de Buenos Aires, Buenos Aires, Argentina** (C Báez Especialista en Epidemiología); **Santa Maria Misericordia Hospital, Udine, Italy** (Prof M Bassetti MD); **Department of Infectious Diseases, University Medical Centre, Ljubljana, Slovenia**

(Prof B Beovic PhD); **Division of Infectious Diseases and Hospital Epidemiology, Kantonsspital St Gallen, St Gallen, Switzerland** (B Bertisch MD); **Institut de Veille Sanitaire, Saint-Maurice, France** (I Bonmarin MD); **National Centre for Immunisation Research and Surveillance, The Children's Hospital at Westmead, University of Sydney, Sydney, NSW, Australia** (Prof R Booy MD); **Instituto Mexicano del Seguro Social, Mexico City, Mexico** (V H Borja-Aburto PhD); **Medical University of Vienna, Vienna, Austria** (Prof H Burgmann MD); **Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China** (Prof B Cao MD); **Department of Infectious Diseases, Hospital Universitari de Bellvitge, Bellvitge Institute for Biomedical Research, L'Hospitalet de Llobregat, Red Española de Investigación en Patología Infecciosa, University of Barcelona, Barcelona, Spain** (Prof J Carratala, PhD); **Victorian Infectious Diseases Service and Department of Microbiology and Immunology, at the Peter Doherty Institute for Infection and Immunity, Parkville, VIC, Australia** (J T Denholm PhD); **Department of Pediatric Infectious Diseases, Children's Hospital Colorado, University of Colorado School of Medicine, Aurora, CO, USA** (S R Dominguez PhD); **Universidade Estadual do Oeste do Paraná, Cascavel, Brazil** (P A D Duarte PhD); **The Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Ramat Gan, Israel** (G Dubnov-Raz MD); **Clinical Virology Laboratory, CEMIC University Hospital, Galvan, Buenos Aires, Argentina** (M Echavarria MD); **Section of Pediatric Infectious Diseases, University of Manitoba, Winnipeg, MB, Canada** (S Fanella MD); **Department of Respiratory and Critical Care Medicine, Peking University People's Hospital, Beijing, China** (Prof Z Gao MD); **Neonatal Intensive Care Unit/Paediatric Intensive Care Unit, Centre Hospitalier Universitaire— Groupe Hospitalier Sud Réunion, Saint Pierre, Réunion, France** (P Gérardin PhD); **Centre for Clinical Investigation 1410, National Institute for Health and Medical Research/Centre**

There is little prepandemic evidence pertaining to the effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza; most evidence comes from observational studies of treatment of seasonal influenza, often in highly specific groups of patients.[3–9] Thus, in 2009–10, neuraminidase inhibitors were used on the basis of rational deduction that they would reduce mortality due to influenza A H1N1pdm09 virus infection rather than on strong pre-existing evidence, although data from treatment of human influenza A H5N1 cases suggested this reduction in mortality might be possible.[10,11] Japanese clinicians used neuraminidase inhibitors widely to treat all people presenting with clinical influenza in 2009–10 and recorded the lowest pandemic mortality rate of any developed country.[12–14] Although a similar treat-all policy existed in the UK in 2009, uptake of neuraminidase inhibitors in patients admitted to hospital with influenza A H1N1pdm09 was low.[15]

Two systematic reviews and meta-analyses have examined the effectiveness of neuraminidase inhibitors in reducing mortality due to influenza. Both suggest substantial reductions in mortality by two-thirds to three-quarters compared with no treatment.[16,17] However, limitations are apparent, such as the heterogeneity of studies included and inadequate adjustment for potential confounding. Importantly, neither was able to adjust for the likelihood of a patient receiving antiviral treatment (propensity)—a crucial consideration when antiviral drugs might have been prioritised towards the sickest patients—and neither was able to use a pooled analysis approach with individual participant data.[18]

Methods

Study design and identification of datasets

The Post-pandemic Review of anti-Influenza Drug Effectiveness (PRIDE) research consortium was set up in October, 2011, and is coordinated by the Health Protection and Influenza Research Group at the University of Nottingham, Nottingham, UK. The aim of the collaboration is to do individual participant data meta-analyses of the effectiveness of antiviral use on outcomes of public health importance during the 2009–10 influenza pandemic. Members of the PRIDE research consortium are listed in appendix pp 1–6.

The initial identification of potential data contributors was done on the basis of a systematic search of 11 databases (date of last search April 19, 2012) for observational studies (case series, case-control, and cohort studies) and randomised controlled trials done between March 1, 2009 (Mexico), or April 1, 2009 (rest of the world), until the WHO declaration of the end of the pandemic (Aug 10, 2010), assessing the association between neuraminidase inhibitor treatment and clinical outcomes (mortality, influenza-related pneumonia, admission to critical care, length of stay in hospital and admission to hospital). We searched Ovid Medline (reports from 1996 onwards) and Embase (1980 onwards) using a comprehensive search

strategy. We also searched CINAHL, CAB Abstracts, ISI Web of Science, PubMed, UK PubMed Central, Scopus, WHO regional indexes, LILAC, and J-STAGE databases using Boolean logic and core search terms relating to pandemic influenza (including influenza A virus OR H1N1 subtype OR swine origin influenza AH1N1 virus) AND exposure of interest—ie, antiviral drugs (including neuraminidase inhibitors OR oseltamivir OR zanamivir OR peramivir) AND clinical outcome measures (including pneumonia, or critical care/intensive care, or mortality). We identified further studies from reference lists of relevant articles and through contact with subject area experts (via JSN-V-T). All search results were limited to human beings with no language restrictions. Our detailed search strategy is reported elsewhere.[17]

On the basis of this search, we contacted 401 potential data contributors, identified during the conduct of our previously reported systematic review;[17] these potential contributors included several corresponding authors from different papers but potentially related to the same source dataset, as an all-inclusive approach. We recruited additional centres through our network of global collaborators, publicity at conferences attended, and by word of mouth. Centres fulfilling the minimum dataset requirement (appendix pp 7–8) were eligible for inclusion. We requested data for both laboratory confirmed and clinically diagnosed pandemic influenza A H1N1pdm09 cases, but allowed centres to provide individual patient data extending to March 14, 2011 (third pandemic wave cases). Clinically diagnosed cases that could not be confirmed by virology were diagnosed on the basis of clinical signs and symptoms that, in the opinion of the attending physician, were judged to be representative of influenza-like illness, in the absence of any other more likely diagnosis. We deliberately accepted diagnoses made on clinical judgment rather than specifying a set of clinical criteria, since case definitions of influenza-like illness vary within and between countries. This study was granted exemption from full ethical review by the University of Nottingham Medical School Research Ethics Committee, provided that each contributing centre held its own institutional review board approval for data collection and sharing.

Data standardisation, exposures, outcomes, and covariates

A common data dictionary was developed and individual datasets standardised according to these definitions (appendix pp 9–15) before pooling for analysis.

The primary outcome variable was mortality, defined as death occurring during admission to hospital or individual study follow-up period for the generalised linear mixed regression models and as death occurring within 30 days of illness onset in the Cox regression models. Use of neuraminidase inhibitors (exposure) was defined and compared as follows: neuraminidase inhibitor treatment (irrespective of timing) versus none; early neuraminidase inhibitor treatment (starting treatment ≤2 days after

symptom onset) versus later (initiation >2 days after symptom onset); early neuraminidase inhibitor treatment versus none; and later neuraminidase inhibitor treatment versus none. Additionally, we created a continuous exposure variable, representing time (in days) between symptom onset and treatment initiation (0 meaning treatment commenced on day of symptom onset). Covariates in the final multivariable models were "inpatient treatment with oral or intravenous antibiotics" and "inpatient treatment with systemic corticosteroids" prescribed during the admission to hospital for influenza along with treatment propensity scores. We were unable to adjust for dose or duration of such treatments because of the scarce availability of these data across the individual datasets.

Propensity scoring

We calculated propensity scores for the likelihood of neuraminidase inhibitor treatment for each patient within individual datasets using multivariable logistic regression for binary treatment variables and generalised propensity score estimation for the continuous time to treatment variable as described by Hirano and Imbens.[19] For each separate study dataset we calculated propensity scores (likelihood of treatment) for each of the four main exposure measures: neuraminidase inhibitor at any time (yes or no), early versus late neuraminidase inhibitor, early versus no neuraminidase inhibitor, and later (>2 days) versus no neuraminidase inhibitor. Covariates were then included as follows, irrespective of significance: age, sex, comorbidity (yes or no), a proxy indicator of severe disease (yes or no), which were, in order of preference, severe respiratory distress; shortness of breath; unweighted symptom score; or, if none of these indicators were available, we used one of the following measures of severity: AVPU (alert, voice, pain, unresponsive) mental status examination score, Glasgow Coma Scale score, Sequential Organ Failure Assessment score, or CURB-65 (confusion, urea, respiratory rate, blood pressure, age ≥65 years) pneumonia severity scores, if these were available, entered as a continuous variable. We added the following variables when available to create an extended model, using a parsimonious approach that retained only significant covariates in the final model: obesity, smoking, pregnancy, asthma, chronic obstructive pulmonary disease, lung disease, heart disease, immunosuppression, neurological disease, renal disease, and diabetes. We rejected variables with more than 25% missing data. Some variables used for the propensity score calculation, such as comorbidity (binary) and illness severity at presentation (binary), were derived at individual study level only and were not appropriate for inclusion in the pooled dataset analysis because of the heterogeneity in definition of these variables between studies.

The appropriateness of the propensity derivation models was assessed graphically by comparing the distribution of estimated propensity scores across treatment groups for


Figure 1: Study flow diagram
*47 overlapping data; one onset of illness before March 1, 2009 (Mexico); nine missing data for key variables.

each individual dataset.[20] Propensity scores were then categorised into quintiles for each individual dataset.

Statistical analysis

We used a generalised linear mixed model to account for clustering of effects by study using the *xtmelogit* command in Stata (version 12). We included "study" as a random intercept to account for differences in baseline crude mortality rate at each site. We adjusted the model for treatment propensity, inpatient antibiotics, and systemic corticosteroids. We included missing data in covariates as a separate dummy category. The overall analysis included patients of all ages with laboratory or clinically diagnosed influenza A H1N1pdm09. We did prespecified stratified analyses for adults and children (<16 years), pregnant women (irrespective of age), laboratory confirmed influenza A H1N1pdm09 cases, and patients admitted to critical care units. Additionally, for a subset of our sample for whom exact onset and treatment initiation times were

Hospitalier Universitaire/ Université de La Réunion, Saint Pierre, Réunion, France (P Gérardin); Unité Mixte de Recherche "Processus Infectieux en Milieu Insulaire Tropical" Université de La Réunion/Centre Hospitalier Universitaire/ National Institute for Health and Medical Research/Research and Development Institute – Cyclotron Réunion Océan Indien, Saint Denis, Réunion, France (P Gérardin); Department of Clinical Microbiology and Infectious Diseases, Hospital General Universitario Gregorio Marañón, Madrid, Spain (M Giannella MD); Department of Infectious Disease Epidemiology, Sector for National Health Documentation and Research, Statens Serum

Institut, Copenhagen, Denmark
(S Gubbels MD); **Section of
Paediatrics, Division of
Infectious Disease, Imperial
College, London, UK**
(J Herberg PhD); **Epidemiology
Research Unit, Instituto
Nacional de Enfermedades
Respiratorias, Ismael Cosío
Villegas, Mexico City, Mexico**
(A L Higuera Iglesias MD); **Catholic
Children's Hospital Wilhelmstift,
Liliencronstr, Hamburg,
Germany** (Prof P H Hoger MD);
**Peking Union Medical College
Hospital, Beijing, China**
(X Hu MD); **Dhaka Medical
College Hospital, Dhaka,
Bangladesh** (Prof Q T Islam FCPS);
**Departamento de Ginecologia e
Obstetrícia, Universidade
Federal de Ciências da Saúde de
Porto Alegre, Preceptora da
Residência Médica do Hospital
Fêmina, Porto Alegre, Brazil**
(M F Jiménez PhD); **Ministry of
Health in Egypt, Cairo, Egypt**
(A Kandeel PhD); **Gold Coast
Hospital, Gold Coast, QLD,
Australia** (G Keijzers MD);
**Department of Clinical
Pharmacy, Faculty of Pharmacy,
Tehran University of Medical
Sciences, Tehran, Iran**
(Prof H Khalili PharmD); **National
Perinatal Epidemiology Unit,
Nuffield Department of
Population Health, University of
Oxford, Oxford, UK**
(Prof M Knight FFPH); **National
Center for Global Health and
Medicine, Tokyo, Japan**
(K Kudo MD); **National Institute
of Respiratory Diseases,
'Dr Emilio Coni', Santa Fe,
Argentina** (G Kusznierz PhD);
**University Hospital for
Infectious Diseases, University
of Zagreb, School of Medicine,
Zagreb, Croatia**
(Prof I Kuzman PhD); **Department
of Intensive Care, Pamela Youde
Nethersole Eastern Hospital,
Chai Wan, Hong Kong, Hong
Kong** (A M C Kwan FHKCP);
**University Mohammed
V-Souissi, Faculty of Medicine
and Pharmacy, Mohammed V
Military Teaching Hospital,
Biosafety Level 3 and Research
Laboratory, Rabat, Morocco**
(Prof I Lahlou Amine PharmD);
**Department of Obstetrics and
Gynaecology, Stellenbosch
University and Tygerberg
Hospital, Cape Town, South
Africa** (E Langenegger MMed);
**Health Policy Research Center,
Shiraz University of Medical
Sciences, Shiraz, Iran**
(Prof K B Lankarani MD);

available, we investigated the association between time to initiation of antiviral treatment and mortality within 30 days of illness onset using a time-dependent Cox regression shared frailty model (to account for clustering by study) adjusted for propensity score and inpatient treatment with antibiotics or systemic corticosteroids. Antiviral treatment was modelled as a time-dependent covariate to overcome immortal time bias (ie, survivor bias). Results from the generalised linear mixed model are expressed as relative risks of mortality using odds ratios (ORs) and hazard ratios (HRs) for the Cox regression analysis with 95% CIs. We used Stata (version 12) for all analyses.

The protocol[21] for this study was registered with the PROSPERO register of systematic reviews, number CRD42011001273.

Role of the funding source

The funder of the study had no role in the study design, data collection, data analysis, data interpretation, or writing of the report. The funder has not and will never have access to the data. Each collaborator had access to the raw data from his or her centre. SGM, SV, PRM, JL-B, and JSN-V-T had access to the pooled dataset. The corresponding author (JSN-V-T) had full access to all the data in the study and the final responsibility for the decision to submit for publication.

Results

We received replies from 128 (32%) of 401 centres contacted; of these 77 (60%) confirmed willingness to participate and the remainder declined (36 [28%] had no data; three [2%] agreed initially but later withdrew because of lack of capacity for data extraction, institutional review board restrictions preventing sharing of individual participant data, or failure to obtain government approval for data sharing; 12 [9%] had agreed in principle, but were unable to share data within project timescales). No data were requested from nor provided by pharmaceutical companies. After exclusion of duplicate responses (same

	All patients	Deceased	Survived
Number of patients*	29 234 (100%)	2784 (10%)	26 450 (90%)
Number of male cases (n=29 226)†	14 431 (49%)	1433 (51%)	12 998 (49%)
Age in years (n=29 034)†	26 (11–44)	40 (26–54)	25 (10–42)
Adults (≥16 years)	19 816 (68%)	2450 (88%)	17 366 (66%)
Children (<16 years)	9218 (32%)	325 (12%)	8893 (34%)
Obese‡ (n=22 527)†	2607 (9%)	517 (19%)	2090 (8%)
Smoking (n=19 066)†	2406 (8%)	285 (10%)	2121 (8%)
Pregnant women§	2166/9513 (23%)	177/951 (19%)	1989/8562 (23%)
WHO region (n=29 234)†			
African	41 (<1%)	14 (1%)	27 (<1%)
Americas	14 186 (49%)	1477 (53%)	12 709 (48%)
Eastern Mediterranean	5262 (18%)	518 (19%)	4744 (18%)
European	7272 (25%)	680 (24%)	6592 (25%)
South-East Asia	210 (1%)	14 (1%)	196 (1%)
Western Pacific	2263 (8%)	81 (3%)	2182 (8%)
Influenza A H1N1pdm09 diagnosis (n=29 234)†			
Laboratory confirmed	25 001 (86%)	2486 (89%)	22 515 (85%)
Clinically diagnosed	4233 (14%)	298 (11%)	3935 (15%)
Comorbidities†¶			
Any comorbidity (n=28 672)	11 011 (38%)	1471 (53%)	9540 (36%)
Asthma (n=20 518)	2820 (10%)	134 (5%)	2686 (10%)
COPD (n=17 081)	1012 (3%)	171 (6%)	841 (3%)
Other chronic lung disease (n=17 853)	2479 (8%)	272 (10%)	2207 (8%)
Heart disease (n=18 419)	1624 (6%)	317 (11%)	1307 (5%)
Renal disease (n=19 860)	710 (2%)	151 (5%)	559 (2%)
Liver disease (n=12 264)	295 (1%)	81 (3%)	214 (1%)
Cerebrovascular disease (n=9803)	304 (1%)	34 (1%)	270 (1%)
Neurological disease (n=13 598)	1013 (3%)	136 (5%)	877 (3%)
Diabetes (n=24 764)	2087 (7%)	418 (15%)	1669 (6%)
Immunosuppression (n=25 268)	1803 (6%)	346 (12%)	1457 (6%)
Pandemic H1N1 vaccination (n=4382)†‖	347/15 349 (2%)	27/1604 (2%)	320/13 745 (2%)
Time from symptom onset to hospital admission in days (n=23 769)†	2 (1–5)	4 (2–6)	2 (1–4)

(Table 1 continues on next page)

	All patients	Deceased	Survived
(Continued from previous page)			
Antiviral agents used			
No NAI treatment	10 431 (36%)	959 (34%)	9472 (36%)
Any NAI	18 803 (64%)	1825 (66%)	16 978 (64%)
Oral oseltamivir**	17 309/18 803 (92%)	1675/1825 (92%)	15 634/16 978 (92%)
Intravenous or inhaled zanamivir**	435/18 803 (2%)	52/1825 (3%)	383/16 978 (2%)
Intravenous peramivir**	49/18 803 (<1%)	28/1825 (2%)	21/16 978 (<1%)
NAI (regimen unknown)**	1251/18 803 (7%)	140/1825 (8%)	1111/16 978 (7%)
NAI and non-NAI**	94/18 803 (<1%)	18/1825 (1%)	76/16 978 (<1%)
NAI combination therapy**	238/18 803 (1%)	69/1825 (4%)	169/16 978 (1%)
Early NAI (≤2 days of symptom onset) (n=13 254)†**	5995/18 803 (32%)	358/1825 (20%)	5637/16 978 (33%)
Later NAI (>2 days after symptom onset) (n=13 254)†**	7259/18 803 (39%)	942/1825 (52%)	6317/16 978 (37%)
Time from symptom onset to antiviral treatment in days (n=12 284)†	3 (1–5)	4 (2–7)	3 (1–5)
Other inhospital treatment†			
Antibiotics (n=20 362)	13 230 (45%)	1096 (39%)	12 134 (46%)
Corticosteroids (n=9982)	2745 (9%)	453 (16%)	2292 (9%)
Hospital length of stay in days (n=22 366)†	5 (2–9)	7 (2–15)	5 (2–8)
Other patient outcomes†			
Influenza-related pneumonia†† (n=16 551)	7225 (25%)	1035 (37%)	6190 (23%)
Admission to critical care (n=24 435)	6848 (23%)	1957 (70%)	4891 (18%)

Data are n (%) or median (IQR). COPD=chronic obstructive pulmonary disease. NAI=neuraminidase inhibitor. *All percentages have been calculated using these denominators unless otherwise specified. †Missing data; n shows number of cases with data. ‡Reported as clinically obese or using WHO definition for obesity (BMI ≥30 kg/m² in adults aged ≥20 years). §Proportions were calculated as a percentage of pregnant patients among female patients of reproductive age (13–54 years); the broader age range was selected in preference to the WHO definition (15–44 years) after consultation with data contributors to reflect the actual fertility experience of the sample. ¶For definition of comorbidity, see appendix pp 9–11. ‖Denominators for pandemic vaccine based on patients admitted after Oct 1, 2009 (when vaccine potentially available). **Percentages calculated as a proportion of the sample receiving NAI therapy. ††Clinically or radiologically diagnosed pneumonia.

Table 1: **Characteristics of pooled dataset of patients admitted to hospital with influenza A H1N1pdm09 virus infection included in mortality analysis**

source dataset), and addition of three further datasets provided through informal contact with domain experts, 80 research groups from 38 countries in six WHO regions contributed anonymised data for 168 117 patients, of whom 24 416 had laboratory results indicative of non-influenza A H1N1 disease. Among the remaining 143 701 laboratory confirmed or clinically diagnosed (without standard study-wide case definition) influenza A H1N1pdm09 cases, 106 138 were outpatients and 2593 had missing information for hospital admission. The remaining 34 970 inpatients were eligible for inclusion (figure 1).

Of the 34 970 inpatients eligible for inclusion, 2095 (6%) had missing information for mortality status, and 3584 (10%) for exposure to neuraminidase inhibitors; 57 (<1%) were unsuitable for inclusion for other reasons (figure 1). Ultimately, we included 29 234 records from 78 studies (two studies provided only outpatient data and were excluded from analysis) of patients admitted to hospital between Jan 2, 2009, and March 14, 2011: 25 001 (86%) laboratory confirmed; 9218 (32%) children; and 1600 (5%) aged 65 years or older. Appendix p 16 show the incidence of cases by month. Full characteristics of the pooled dataset are listed in table 1 with absolute risks of mortality for various exposure categories and subgroups summarised in appendix

p 16. Baseline characteristics of each constituent dataset are presented in appendix pp 17–21.

Patients without neuraminidase inhibitor treatment data and therefore excluded from analysis were more likely to be older, to have presented to hospital later, less likely to have a laboratory confirmed diagnosis, and more likely to be treated with antibiotics than were patients included in the analysis (appendix pp 26–27). However, they were less likely to be smokers, obese, or to have an underlying comorbidity. Additionally, their hospital stay was shorter, and they were less likely to have severe outcomes (admission to critical care unit or death), or influenza-related pneumonia (appendix pp 26–27).

After adjustment for propensity score and corticosteroid and antibiotic treatment, the likelihood of mortality in patients treated with a neuraminidase inhibitor was 0·81 (95% CI 0·70–0·93), compared with no treatment (table 2). The OR did not change substantially when only laboratory confirmed cases were included (adjusted OR 0·82 [95% CI 0·70–0·95]). Similarly, we identified significant associations with a reduced mortality risk in adults, pregnant women, and critically ill adult patients (table 2). However, there was no significant association between neuraminidase inhibitor treatment and mortality in children aged 0–15 years (table 2). Post-hoc analyses restricted to

Department of Infectious Diseases, Tan Tock Seng Hospital, Singapore, Singapore (Y-S Leo FRCP); Helsinki University Hospital, Helsinki, Finland (R Linko PhD); Department of Infectious Diseases, the First Affiliated Hospital, China Medical University, Shenyang, China (Prof P Liu MD); King Hussein Cancer Center, Department of Pediatrics, Amman, Jordan (Prof F Madanat MD); Instituto de Medicina Preventiva de la Defensa, Capitan Medico Ramon y Cajal, Ministerio de Defensa, Madrid, Spain (E Mayo-Montero PhD); Toronto Invasive Bacterial Diseases Network, University of Toronto, Toronto, ON, Canada (Prof A McGeer MD); Ministry of Health, Riyadh, Saudi Arabia (Prof Z Memish FRCPC); College of Medicine, Alfaisal University, Riyadh, Saudi Arabia (Prof Z Memish); Department of Infectious Diseases and Clinical Microbiology, Erciyes University Faculty of Medicine, Kayseri, Turkey (G Metan MD); Lithuanian University of Health Sciences, Kaunas, Lithuania (A Mickiene PhD); Military Medical Academy, Clinic for Infectious and Tropical Diseases, Belgrade, Serbia (Prof D Mikić PhD); Section for Infectious Diseases, Medical Department, and Department of Research and Development, Haukeland University Hospital, Bergen, Norway (K G I Mohn MD); The Influenza Centre, Department of Clinical Science, University of Bergen, Bergen, Norway (K G I Mohn); The Division of Ocular Immunology, Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, MD, USA (A Moradi MD); National Research Institute for Tuberculosis and Lung Disease, Massih Daneshvari Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran (A Moradi); National Influenza Center, National Center of Communicable Diseases, Ministry of Health, Ulaanbaatar, Mongolia (Prof P Nymadawa PhD); Department of Infection Control, Hospital San Martín de Paraná, Entre Ríos, Argentina (M E Oliva MD); Dr Sami Ulus Research and Training Hospital of Women's and Children's Health and Diseases, Clinic of

Pediatric Neurology, Ankara,
Turkey (M Ozkan MD); **Critical
Care and Pain Perioperative,
Critical Care and Trauma Trials
Group , School of Clinical and
Experimental Medicine,
University of Birmingham, UK**
(D Parekh MRCP); **Division of
Infectious Diseases, Rambam
Health Care Campus, Haifa, Israel**
(M Paul MD); **Vanderbilt Vaccine
Center, Department of
Pediatrics, Vanderbilt University,
Nashville, TN, USA**
(Prof F P Polack MD); **Fundacion
INFANT, Buenos Aires,
Argentina** (Prof F P Polack);
**Department of Pediatrics,
Division of Pneumonology-
Immunology, Charité University
Medical Center, Berlin, Germany**
(B A Rath PhD); **Hospital Joan
XXIII, Critical Care Department,
Institut d'Investigació Sanitària
Pere Virgili, Universitat Rovira i
Virgili, Ciber De Enfermedades
Respiratorias, Tarragona, Spain**
(A H Rodríguez PhD); **Ministerio
de Salud de Tucumán, Tucumán,
Argentina** (E B Sarrouf MD);
**Paediatric Intensive Care Unit,
Bristol Children's Hospital,
Bristol, UK** (A C Seale MSc);
**Bristol Children's Vaccine Centre,
School of Clinical Sciences,
University of Bristol, Bristol, UK**
(A C Seale); **Yuzuncu Yil
University Medical Faculty,
Department of Pulmonary
Medicine, Van, Turkey**
(B Sertogullarindan MD);
**Laboratory of Respiratory
Viruses, Oswaldo Cruz Institute/
Fiocruz, Rio de Janeiro, Brazil**
(M M Siqueira PhD); **Uniwersytet
Rzeszowski, Rzeszów, Poland**
(Prof J Skręt-Magierło MD);
**Department of Emergency
Medicine, University Hospital
Basel, Basel, Switzerland**
(F Stephan MD); **Department of
Children's Infectious Diseases,
Medical University of Warsaw,
Warsaw, Poland** (E Talarek PhD);
**Division of Microbiology,
Molecular Diagnostic Centre,
Department of Laboratory
Medicine National University
Hospital, Singapore, Singapore**
(J W Tang FRCPath); **Alberta
Provincial Laboratory for Public
Health, University of Alberta
Hospital, Edmonton, AB, Canada**
(J W Tang); **Department of
Medical Microbiology and
Immunology, University of
Alberta, Edmonton, AB, Canada**
(J W Tang); **Carol Yu Centre for
Infection and Division of
Infectious Diseases, Department
of Microbiology, The University**

	Crude analysis		Adjusted* analysis	
	OR (95% CI)	p value	OR (95% CI)	p value
Laboratory confirmed or clinically diagnosed, all ages; n=29 234	0·92 (0·81–1·05)	0·21	0·81 (0·70–0·93)	0·0024
Laboratory confirmed cases, all ages; n=25 001	0·94 (0·81–1·09)	0·42	0·82 (0·70 to 0·95)	0·0104
Adults (≥16 years); n=19 816	0·82 (0·70–0·95)	0·0071	0·75 (0·64–0·87)	0·0002
Children (<16 years); n=9218	1·02 (0·73–1·42)	0·90	0·82 (0·58–1·17)	0·28
Pregnant women; n=2166	0·47 (0·24–0·90)	0·0228	0·46 (0·23–0·89)	0·0215
Critical care patients				
Adults (≥16 years); n=5103	0·74 (0·57–0·95)	0·0187	0·72 (0·56–0·94)	0·0155
Children (<16 years); n=1725	0·84 (0·52–1·37)	0·49	0·70 (0·42–1·16)	0·17

OR=odds ratio. *Adjusted for treatment propensity (by quintile), corticosteroid use, and antibiotic use.

Table 2: Neuraminidase inhibitor treatment (at any time) versus none

	Crude analysis		Adjusted* analysis	
	OR (95% CI)	p value	OR (95% CI)	p value
Early treatment versus later treatment				
Laboratory confirmed or clinically diagnosed, all ages; n=13 254	0·36 (0·31–0·41)	<0·0001	0·48 (0·41–0·56)	<0·0001
Laboratory confirmed cases, all ages; n=12 992	0·36 (0·31–0·41)	<0·0001	0·48 (0·41–0·56)	<0·0001
Adults (≥16 years); n=9270	0·37 (0·32–0·44)	<0·0001	0·45 (0·38–0·54)	<0·0001
Children (<16 years); n=3899	0·53 (0·35–0·80)	0·0026	0·67 (0·44–1·03)	0·07
Pregnant women; n=917	0·20 (0·09–0·46)	0·0002	0·27 (0·11–0·63)	0·0026
Critical care patients				
Adults (≥16 years); n=3385	0·64 (0·51–0·79)	<0·0001	0·62 (0·49–0·77)	<0·0001
Children (<16 years); n=683	1·12 (0·63–1·99)	0·69	1·15 (0·64–2·06)	0·64
Early treatment versus none				
Laboratory confirmed or clinically diagnosed, all ages; n=16 425	0·54 (0·40–0·72)	<0·0001	0·50 (0·37–0·67)	<0·0001
Laboratory confirmed cases, all ages; n=13 200	0·53 (0·39–0·71)	<0·0001	0·48 (0·36–0·66)	<0·0001
Adults (≥16 years); n=10 607	0·39 (0·28–0·55)	<0·0001	0·38 (0·27–0·54)	<0·0001
Children (<16 years); n=5696	1·08 (0·61–1·93)	0·79	0·85 (0·47–1·53)	0·59
Pregnant women; n=1303	0·16 (0·04–0·64)	0·0099	0·16 (0·04–0·67)	0·0118
Critical care patients				
Adults (≥16 years); n=1608	0·30 (0·19–0·45)	<0·0001	0·31 (0·20–0·47)	<0·0001
Children (<16 years); n=572	0·88 (0·40–1·91)	0·74	0·76 (0·34–1·67)	0·49

OR=odds ratio. *Adjusted for treatment propensity (by quintile), corticosteroid use, and antibiotic use.

Table 3: Early neuraminidase inhibitor treatment (≤2 days after onset) versus later (>2 days) or none

	Crude analysis		Adjusted* analysis	
	OR (95% CI)	p value	OR (95% CI)	p value
Laboratory confirmed or clinically diagnosed, all ages; n=17 670	1·27 (1·00–1·61)	0·0497	1·20 (0·93–1·54)	0·15
Laboratory confirmed cases, all ages; n=14 409	1·25 (0·98–1·59)	0·07	1·17 (0·92–1·51)	0·21
Adults (≥16 years); n=12 269	1·01 (0·77–1·32)	0·94	1·01 (0·76–1·33)	0·96
Children (<16 years); n=5282	1·34 (0·78–2·31)	0·29	1·29 (0·75–2·21)	0·36
Pregnant women; n=1302	0·72 (0·26–2·01)	0·53	0·70 (0·24–2·06)	0·51
Critical care patients				
Adults (≥16 years); n=2977	0·61 (0·43–0·86)	0·0045	0·65 (0·46–0·93)	0·0183
Children (<16 years); n=644	0·65 (0·32–1·36)	0·25	0·75 (0·35–1·57)	0·44

OR=odds ratio. *Adjusted for treatment propensity quintiles, corticosteroid use and antibiotic use.

Table 4: Later neuraminidase inhibitor treatment (>2 days) versus none

children up to 1 year of age and up to 5 years of age did not change this finding (appendix p 27).

Early neuraminidase inhibitor treatment compared with later treatment initiation was associated with an overall significant reduction in mortality risk (adjusted OR 0·48 [95% CI 0·41–0·56]; table 3). The ORs remained essentially unchanged when only laboratory confirmed cases were considered, but risk reduction was higher in pregnant women (table 3). Notably, there was again no significant association between early treatment and mortality in children after adjustment (table 3).

Neuraminidase inhibitor treatment within 2 days of symptom onset compared with none was also associated with a significant reduction in mortality in all patients (adjusted OR 0·50 [95% CI 0·37–0·67]; table 3), with significant risk reductions also noted among laboratory confirmed cases, adults, pregnant women, and adult patients admitted to critical care (table 3). However, there was no significant association with a lower mortality risk in children aged 0–15 years (table 3).

With regard to neuraminidase inhibitor treatment started more than 2 days after symptom onset compared with none, we identified no significant association with mortality in all patients (adjusted OR 1·20 [95% CI 0·93–1·54]), nor in laboratory confirmed cases, adults, pregnant women, or children (table 4). However, we noted an associated mortality risk reduction of about a third (adjusted OR 0·65 [95% CI 0·46–0·93]) in adult patients admitted to critical care.

Information about exact timing of neuraminidase inhibitor treatment from symptom onset was available for 65% (12284 of 18803) of those receiving such treatment. After taking into account clustering by study, propensity score quintiles, and inhospital treatment with antibiotics or systemic corticosteroids, when antiviral use was modelled as a time-dependent covariate to overcome potential immortal time bias (ie, survivor bias), neuraminidase inhibitor treatment was significantly associated with decreased hazard rate of mortality over a 30-day follow-up period (adjusted HR 0·51 [95% CI 0·45–0·58], p<0·0001) as compared with no antiviral treatment. When only treated cases were included, there was an increase in the hazard with each day's delay in initiation of treatment up to day 5 as compared with treatment initiated within 2 days of symptom onset (adjusted HR 1·23 [95% CI 1·18–1·28], p<0·0001 for the increasing HR with each day's delay). The unadjusted and adjusted survival curves comparing survival by time to treatment initiation are shown in figure 2 and appendix pp 28–29.

Discussion

Our results show that neuraminidase inhibitor treatment was associated with reduced mortality in adult patients admitted to hospital with influenza A H1N1pdm09 virus infection. Neuraminidase inhibitor treatment of influenza A H1N1pdm09 at any stage of


Figure 2: Survival by time to treatment
HR=hazard ratio. NAI=neuraminidase inhibitor. *Cox regression shared frailty model (adjusted for treatment propensity and in hospital steroid or antibiotic use).

Number at risk				
Early NAI treatment (within 2 days)	5192	2414	1939	1843
Treated with NAI day 3	1477	689	492	460
Treated with NAI day 4	1012	567	322	282
Treated with NAI day 5	812	541	272	241
Treated with NAI after day 5	2298	1981	1009	735

illness compared with none revealed an associated reduction in the likelihood of mortality (table 2). We identified an associated likelihood of lower mortality when comparing early versus later initiation of treatment and when comparing early treatment with none (table 3, panel). Although we included 4233 patients (14%) without laboratory confirmed influenza A H1N1pdm09, restriction to laboratory-confirmed cases produced near identical estimates, suggesting that the data are not confounded by misclassification bias attributable to other causes (tables 2, 3). Additionally, we noted much the same findings in adults, pregnant women, and adult patients needing admission to critical care. The finding regarding critical care suggests that neuraminidase inhibitors were associated with mortality reduction across the spectrum of severity in adult patients admitted to hospital with influenza A H1N1pdm09. These findings accord closely with previous studies[16,17] but have increased precision and reduced estimates of effectiveness consistent with more complete adjustment for confounders and treatment propensity. They are also consistent with ecological data.[23–25]

We were consistently unable to show any association of neuraminidase inhibitor treatment with mortality reduction in children. Possible explanations include lower case fatality proportion in paediatric patients (thus reduced statistical power),[26,27] higher influenza A H1N1pdm09 viral

of Hong Kong, Queen Mary Hospital, Hong Kong (K K W To FRCPath); Hospital Clinic, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Ciber De Enfermedades Respiratorias, Barcelona, Spain (A Torres PhD); Department of Pediatric Infectious Diseases, Istanbul Medical Faculty, Istanbul, Turkey (S H Törün MD); Division of Infectious Diseases, Department of Paediatrics, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada (D Tran MD); Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA (T M Uyeki MD); Department of Pediatric Intensive Care, VU University Medical Center, Amsterdam, Netherlands (A Van Zwol PhD); Division of Infectious Diseases, Department of Pediatrics, University of Alberta, Stollery Children's Hospital, Edmonton, AB, Canada (W Vaudry MD); General Hospital Slovenj Gradec, Slovenj Gradec, Slovenia

Systematic review

Two systematic reviews and meta-analyses have examined the effectiveness of neuraminidase inhibitors in reducing mortality due to influenza. Hsu and colleagues[16] considered reported observational data, mainly for seasonal influenza, and concluded that oral oseltamivir might reduce mortality (odds ratio [OR] 0·23 [95% CI 0·13–0·43]). In our own systematic review, we included only reported data from the 2009–10 influenza A H1N1 pandemic (all observational) and showed that early neuraminidase inhibitor treatment versus none reduced mortality by two thirds (OR 0·35 [95% CI 0·18–0·71]).[17] We applied search terms relating to pandemic influenza (including "Influenza A Virus" OR "H1N1 Subtype" OR "swine origin influenza AH1N1 virus"), AND exposure of interest—ie, antiviral drugs (including "neuraminidase inhibitors" OR "oseltamivir" OR "zanamivir" OR "peramivir") AND clinical outcome measures (including "pneumonia", "critical or intensive care", "mortality") to 11 databases (search range from Jan 1, 2009, to Aug 10, 2010; last search on April 19, 2012) without imposing language restrictions. Importantly, both studies acknowledged limitations such as the heterogeneity of studies included and inadequate adjustment for potential confounding. Moreover, neither was able to adjust for the likelihood of a patient receiving antiviral treatment (propensity)—a crucial consideration when antiviral drugs might have been prioritised towards the sickest patients.

Interpretation

By using a meta-analysis of individual patient data, which permits a uniform approach to potential confounding and adjustment for treatment propensity, and through the assembly of a very large international dataset, our study adds substantially to the evidence that neuraminidase inhibitors administered to adults admitted to hospital with influenza A H1N1pdm09 reduced mortality, especially when started promptly. Since placebo-controlled randomised controlled trials of neuraminidase inhibitors are not ethically feasible during a pandemic, the evidence we have assembled is likely to be the best that will be available. The US Centers for Disease Control and Prevention recommend neuraminidase inhibitor treatment as early as possible for any patient with confirmed or suspected influenza who is hospitalised; has severe, complicated or progressive illness; or is at higher risk for influenza complications.[22] Neuraminidase inhibitors are also widely prescribed in Japan, but elsewhere their use is far less common. Although a similar treat-all policy existed in the UK in 2009, uptake of neuraminidase inhibitors inpatients admitted to hospital with influenza A H1N1pdm09 virus was low.[15] We advocate early instigation of neuraminidase inhibitor treatment in adults admitted to hospital with suspected or proven influenza infection.

(T Vidmar MD); **Departamento de Vigilância Epidemiológica, Secretaria de Vigilância em Saúde, Ministério da Saúde, Brasília DF, Brazil** (R T C Yokota MSc); **and Unit of Infectious Diseases, University General Hospital of Alexandroupolis, Democritus University Thrace, Dragana, Greece** (P Zarogoulidis PhD)
Correspondence to:
Prof Jonathan Nguyen-Van-Tam, Clinical Sciences Building, University of Nottingham, City Hospital, Nottingham NG5 1PB, UK
jvt@nottingham.ac.uk

See **Online** for appendix

load in children[28] than adults leading to reduced drug effectiveness, suboptimum dosing in very young children,[29] secondary bacterial infections (eg, meticillin-resistant *Staphylococcus aureus*), confounding by indication[30] (children might have been more likely to have had antivirals prescribed if they had more severe disease or if they failed to respond to other treatments), or a combination of these factors. Since it has been suggested that younger children might be admitted with milder disease compared with older children and adults (precautionary physician behaviour), that the pharma-cokinetics and pharmacology of oseltamivir might be different in very young children,[29] and that influenza pathogenesis might differ by age,[30] we did post-hoc sensitivity analyses separately in children up to 1 year of age and up to 5 years of age, but our findings did not change (appendix p 27). However, we note that these results contrast with those of Louie and colleagues,[32] who recently showed a two-thirds reduction in mortality among

children treated with neuraminidase inhibitors admitted to hospital with influenza (OR 0·36 [95% CI 0·16–0·83]).

The finding that no treatment was better than late treatment is probably explained by confounding due to illness severity at the point of treatment initiation (ie, confounding by indication). Untreated patients probably had milder disease and patients treated later in the course of their illness might have had delays in hospital admission, delays in diagnosis after admission, or delays in being considered for neuraminidase inhibitor treatment (treatment only started once their condition deteriorated), or combinations of these factors. We advocate early consideration of a diagnosis of influenza in patients admitted to hospital with respiratory infection during periods of known influenza activity, and early instigation of neuraminidase inhibitor treatment based on rapid laboratory confirmation or clinical suspicion.

Our analyses examining the effect of later treatment versus none are especially relevant to the continued clinical debate about the value of delayed therapy. Combining all subgroups of patients, we did not identify any protective association with treatment delayed more than 2 days after symptom onset (table 4). This finding could be explained by confounding by indication. However, we noted that in adult patients admitted to critical care, delayed treatment was associated with reduced likelihood of mortality compared with no treatment (table 4), suggesting that delayed therapy might still be worthwhile in severely ill patients; this finding is plausible since, within this subgroup, treated and untreated patients (who all needed admission to critical care) are likely to have been more balanced in terms of illness severity thereby overcoming confounding by this factor to some extent. Additionally, some patients admitted to critical care might have had prolonged influenza A H1N1pdm09 virus replication in the lower respiratory tract, which might benefit from later initiation of neuraminidase inhibitor treatment. To gain further understanding about overall timing-dependent benefit, we modelled time to start of antiviral treatment using a time-dependent Cox regression model, which showed a significant detrimental survival benefit associated with delay in treatment beyond 2 days after symptom onset (p<0·0001), albeit with overlapping 95% CIs when time to treatment was modelled as a categorical variable; the latter finding suggests that potential differences in treatment benefit between starting on day 3 after symptom onset through to more than 5 days after symptom onset cannot be further clarified through our data. This finding could seem to conflict with the findings in table 4 comparing later neuraminidase inhibitor treatment to no neuraminidase inhibitor treatment but is not surprising, because by comparing only treated patients in figure 2, we possibly eliminated some of the confounding due to indication, which allowed us to identify the potential survival benefits conferred by later treatment, albeit detrimental in proportion to treatment delay.

One of the strengths of this study is the very large number of patients from geographically diverse clinical centres and source populations. We made exhaustive efforts to identify suitable datasets from around the world, but nevertheless cannot comment on the extent to which bias might have been introduced by failing to include centres that did not respond (we cannot say if they had suitable data or not), or that declined to share data; in a worst case scenario, it is possible that less than 20% of potential sites contributed to this analysis. Furthermore, comparatively few cases were from the WHO African (0·1%) and South-East Asia (0·7%) regions, which might limit the extent to which our findings can be generalised.

A clear limitation of our study is that we were unable to adjust specifically for disease severity in our multilevel models because of the heterogeneity of severity measures used across individual datasets. However, we made every effort to include relevant data including severity measures, within each propensity score, but there is still likely to be some residual confounding, particularly due to illness severity at presentation. Likewise, we attempted to control for study-level biases, such as treatment policies, and health-care seeking behaviour, using multilevel models but there might be residual confounding. A further limitation of our dataset is that 10% of the patients had missing data for exposure to neuraminidase inhibitors and were excluded from the analysis; the characteristics of these patients are compared with those with data for neuraminidase inhibitor exposure in appendix pp 26–27; these patients were more likely to be older, to have presented to hospital later, less likely to have a laboratory confirmed diagnosis, and more likely to be treated with antibiotics.

The decision to adjust for treatment with antibiotics and corticosteroids was taken after consultation with clinical colleagues within the PRIDE study collaboration. This decision results from widespread clinical practice to treat patients admitted to hospital with respiratory illness with corticosteroids and antibiotics. There is particular uncertainty about the possible effect of corticosteroids on the course of severe influenza infection.[33,34] Therefore, it was necessary to separate out the possible effects of antivirals from these other commonly used treatments. We did not do specific analyses to establish the potential effect of antibiotic or corticosteroid use on mortality, but recognise that these factors both warrant further research. Although we were able to adjust for inpatient antibiotics and systemic corticosteroid use, we were unable to adjust for pandemic H1N1 vaccination since 35% (8284 of 23633) of our case series were admitted to hospital before the first availability of vaccine in October, 2009, and 71% (10967 of 15349) of data for vaccination status were missing among those admitted after that juncture; however, the available data suggest uptake was no higher than 8% during the study period.

This meta-analysis of individual patient data offers the most rigorous assessment of mortality benefits of neuraminidase inhibitor treatment during the 2009–10 pandemic that is likely to be possible using retrospective observational data. The greatest likelihood of reduced mortality seems to be attributable to treatment started within 2 days of symptom onset. These data offer evidence of the effectiveness of neuraminidase inhibitors during the 2009–10 pandemic and are superior to extrapolations from earlier data on seasonal influenza; they could retrospectively vindicate prepandemic neuraminidase inhibitor antiviral stockpiling decisions made by governments worldwide. Treatment guidance policies should increase emphasis on early empirical neuraminidase inhibitor treatment of adult patients admitted to hospital after presenting with proven or clinically suspected influenza A H1N1pdm09 virus infection. However, most adult patients with suspected or confirmed influenza are not admitted to hospital within 48 h of illness onset. Therefore, the implications of these findings, although based on patients admitted to hospital with influenza A H1N1pdm09, encourage early initiation of neuraminidase inhibitor treatment in outpatients who are appreciably unwell with suspected or confirmed influenza, or at increased risk of complications, including those with influenza A H3N2 or influenza B. Further studies are needed in children to confirm the adequacy of present dose regimens and duration of therapy in terms of clinical efficacy.

Contributors

JSN-V-T, PRM, SGM, SV, and JL-B conceived and designed the study. All authors, apart from SGM, SV, and JL-B, contributed to acquisition and local preparation of constituent datasets. SGM, SV, PRM, and JL-B contributed to dataset amalgamation and standardisation, design of statistical analyses, and data analysis. JSN-V-T, PRM, SGM, SV, and JL-B interpreted the data and wrote the paper. All authors contributed to critical examination of the paper for important intellectual content and approval of the final report. Each author acts as the guarantor of data from their individual study centre; JSN-V-T and PRM act as overall guarantors for the pooled analysis and the report.

PRIDE Consortium Investigators

Maria De Lourdes Aguiar-Oliveira, Malakita Al Masri, Robed Amin, Wildo N Araújo, Elena Ballester-Orcal, Carlos Bantar, Jing Bao, Mazen M Barhoush, Ariful Basher, Edgar Bautista, Julie Bettinger, Roland Bingisser, Emilio Bouza, Ilkay Bozkurt, Elvira Čeljuska-Tošev, Kenny K C Chan, Yusheng Chen, Tserendorj Chinbayar, Catia Cilloniz, Rebecca J Cox, María R Cuezzo, Wei Cui, Simin Dashti-Khavidaki, Bin Du, Hicham El Rhaffouli, Hernan Escobar, Agnieszka Florek-Michalska, James Fraser, John Gerrard, Stuart Gormley, Sandra Götberg, Matthias Hoffmann, Behnam Honarvar, Jianmin Hu, Christoph Kemen, Gulam Khandaker, Evelyn S C Koay, Miroslav Kojic, Win M Kyaw, Leonard Leibovici, Hongru Li, Xiao-Li Li, Romina Libster, Tze P Loh, Deborough Macbeth, Efstratios Maltezos, Toshie Manabe, Débora N Marcone, Magdalena Marczynska, Fabiane P Mastalir, Mohsen Moghadami, Lilian Moriconi, Bulent Ozbay, Blaž Pečavar, Wolfgang Poeppl, Philippe G Poliquin, Mahmudur Rahman, Alberto Rascon-Pacheco, Samir Refaey, Brunhilde Schweiger, Fang G Smith, Ayper Somer, Thiago M L Souza, Payam Tabarsi, Chandrabhanu B Tripathi, Daiva Velyvyte, Diego Viasus, Qin Yu, Kwok-Yung Yuen, Wei Zhang, Wei Zuo. Affiliations listed in appendix pp 1–6.

References
1 Donner B, Bader-Weder S, Schwarz R, Peng MM, Smith JR, Niranjan V. Safety profile of oseltamivir during the 2009 influenza pandemic. *Pharmacoepidemiol Drug Saf* 2011; **20:** 532–43.
2 Atkins CY, Patel A, Taylor TH Jr, et al. Estimating effect of antiviral drug use during pandemic (H1N1) 2009 outbreak, United States. *Emerg Infect Dis* 2011; **17:** 1591–98.
3 Chemaly RF, Ghosh S, Bodey GP, et al. Respiratory viral infections in adults with hematologic malignancies and human stem cell transplantation recipients: a retrospective study at a major cancer center. *Medicine (Baltimore)* 2006; **85:** 278–87.
4 Chemaly RF, Torres HA, Aguilera EA, et al. Neuraminidase inhibitors improve outcome of patients with leukemia and influenza: an observational study. *Clin Infect Dis* 2007; **44:** 964–67.
5 Hassan K, McGeer A, Green KA, et al. Antiviral therapy improves outcomes of influenza infections in patients requiring admission to intensive care. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy; San Francisco, CA; Sept 12–15, 2009. V-537.
6 Lee N, Choi KW, Chan PK, et al. Outcomes of adults hospitalised with severe influenza. *Thorax* 2010; **65:** 510–15.
7 McGeer A, Green KA, Plevneshi A, et al. Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario, Canada. *Clin Infect Dis* 2007; **45:** 1568–75.
8 Nichols WG, Guthrie KA, Corey L, Boeckh M. Influenza infections after hematopoietic stem cell transplantation: risk factors, mortality, and the effect of antiviral therapy. *Clin Infect Dis* 2004; **39:** 1300–06.
9 Hanshaoworakul W, Simmerman JM, Narueponjirakul U, et al. Severe human influenza infections in Thailand: oseltamivir treatment and risk factors for fatal outcome. *PLoS One* 2009; **4:** e6051.
10 Adisasmito W, Chan PKS, Lee N, et al. Effectiveness of antiviral treatment in human influenza A(H5N1) infections: analysis of a global patient registry. *J Infect Dis* 2010; **202:** 1154–60.
11 Chan PKS, Lee N, Zaman M, et al. Determinants of antiviral effectiveness in influenza virus A subtype H5N1. *J Infect Dis* 2012; **206:** 1359–66.
12 Nakai A, Minakami H, Unno N, et al. Characteristics of pregnant Japanese women who required hospitalization for treatment of pandemic (H1N1) 2009--low mortality rate may be due to early antiviral use. *J Infect* 2011; **62:** 232–33.
13 Sugaya N. Widespread use of neuraminidase inhibitors in Japan. *J Infect Chemother* 2011; **17:** 595–601.
14 Sugaya N, Shinjoh M, Mitamura K, Takahashi T. Very low pandemic influenza A (H1N1) 2009 mortality associated with early neuraminidase inhibitor treatment in Japan: analysis of 1000 hospitalized children. *J Infect* 2011; **63:** 288–94.
15 Myles PR, Semple MG, Lim WS, et al, for the Influenza Clinical Information Network (FLU-CIN). Predictors of clinical outcome in a national hospitalised cohort across both waves of the influenza A/H1N1 pandemic 2009–2010 in the UK. *Thorax* 2012; **67:** 709–17.
16 Hsu J, Santesso N, Mustafa R, et al. Antivirals for treatment of influenza: a systematic review and meta-analysis of observational studies. *Ann Intern Med* 2012; **156:** 512–24.
17 Muthuri SG, Myles PR, Venkatesan S, Leonardi-Bee J, Nguyen-Van-Tam JS. Impact of neuraminidase inhibitor treatment on outcomes of public health importance during the 2009-2010 influenza A(H1N1) pandemic: a systematic review and meta-analysis in hospitalized patients. *J Infect Dis* 2013; **207:** 553–63.
18 Riley RD, Lambert PC, Abo-Zaid G. Meta-analysis of individual participant data: rationale, conduct, and reporting. *BMJ* 2010; **340:** c221.
19 Hirano K, Imbens GW. The propensity score with continuous treatments. In: Gelman A, Meng X-L, eds. Applied Bayesian modeling and causal inference from incomplete-data perspectives. Hoboken: Wiley, 2004: 73–84.
20 Harder VS, Stuart EA, Anthony JC. Propensity score techniques and the assessment of measured covariate balance to test causal associations in psychological research. *Psychol Methods* 2010; **15:** 234–49.
21 Myles P, Leonardi-Bee J, Van-Tam J, Muthuri S, Venkatesan S. A systematic review of the impact of neuraminidase inhibitor antiviral use on outcomes of public health importance during the 2009/10 (swine) influenza A/H1N1v pandemic. http://www.crd.york.ac.uk/NIHR_PROSPERO/display_record.asp?ID=CRD42011001273#.UvDWqFFNKW8 (accessed Feb 4, 2014).
22 Centers for Disease Control and Prevention. Influenza antiviral medications: summary for clinicians. http://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm#summary (accessed March 14, 2014).
23 Transmission dynamics and impact of pandemic influenza A (H1N1) 2009 virus. *Wkly Epidemiol Rec* 2009; **84:** 481–84.
24 Chowell G, Viboud C, Simonsen L, et al. Impact of antiviral treatment and hospital admission delay on risk of death associated with 2009 A/H1N1 pandemic influenza in Mexico. *BMC Infect Dis* 2012; **12:** 97.
25 Miller PE, Rambachan A, Hubbard RJ, et al. Supply of neuraminidase inhibitors related to reduced influenza A (H1N1) mortality during the 2009-2010 H1N1 pandemic: an ecological study. *PLoS One* 2012; **7:** e43491.
26 Van Kerkhove MD, Vandemaele KAH, Shinde V, et al. Risk factors for severe outcomes following 2009 influenza A (H1N1) infection: a global pooled analysis. *PLoS Med* 2011; **8:** e1001053.
27 Wong JY, Kelly H, Ip DKM, Wu JT, Leung GM, Cowling BJ. Case fatality risk of influenza A(H1N1pdm09): a systematic review. *Epidemiology* 2013; **24:** 830–41.
28 Li C-C, Wang L, Eng H-L, et al. Correlation of pandemic (H1N1) 2009 viral load with disease severity and prolonged viral shedding in children. *Emerg Infect Dis* 2010; **16:** 1265–72.
29 Kimberlin DW, Acosta EP, Prichard MN, et al. Oseltamivir pharmacokinetics, dosing, and resistance among children aged <2 years with influenza. *J Infect Dis* 2013; **207:** 709–20.
30 Signorello LB, McLaughlin JK, Lipworth L, Friis S, Sorensen HT, Blot WJ. Confounding by indication in epidemiologic studies of commonly used analgesics. *Am J Ther* 2002; **9:** 199–205.
31 Sun S, Zhao G, Xiao W, et al. Age-related sensitivity and pathological differences in infections by 2009 pandemic influenza A (H1N1) virus. *Virology J* 2011; **8:** 52.
32 Louie JK, Yang S, Samuel MC, Uyeki TM, Schechter R. Neuraminidase Inhibitors for Critically Ill Children With Influenza. *Pediatrics* 2013; **132:** e1539–45.
33 Hui DSC, Lee N. Adjunctive therapies and immunomodulating agents for severe influenza. *Influenza Other Respir Viruses* 2013; **7** (suppl 3)**:** 52–59.
34 Myles P, Nguyen-Van-Tam JS, Semple MG, et al. Differences between asthmatics and nonasthmatics hospitalised with influenza A infection. *Eur Respir J* 2013; **41:** 824–31.